Anticytotoxic T lymphocyte-associated antigen 4 treatment--can melanoma be cured at the expense of autoimmune disorders?
Lejeune
Ferdy J
FJ
D000911:Antibodies, Monoclonal / Q000737:chemistry; D015703:Antigens, CD / Q000737:chemistry / Q000276:immunology*; D000943:Antigens, Differentiation / Q000737:chemistry / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000378:metabolism; D001327:Autoimmune Diseases / Q000628:therapy*; D015551:Autoimmunity; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008545:Melanoma / Q000276:immunology* / Q000628:therapy*; D016377:Organ Transplantation / Q000379:methods; D012878:Skin Neoplasms / Q000276:immunology* / Q000628:therapy
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D019496:Cancer Vaccines